Cellnovo Group ("Cellnovo"), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, today announces the launch of its initial public offering on the regulated market of Euronext Paris. Following the registration of its document de base under number I.15-008 on February 27, 2015, the Autorité des marchés financiers (AMF) granted visa n°15-313 on June 26th, 2015, for the prospectus relative to the listing of Cellnovo.